Before Wellbeing: Reconstructing the Organisation That Came Before the Foundation

What existed before Wellbeing International Foundation?

It sounds like a simple question.

It isn't.

Wellbeing today presents itself as an international organisation built around Cell-Free Therapy, with a German laboratory, a network of partner clinics, a central management team and a scientific history it says stretches back decades.

Its current website describes a research heritage extending well before the modern organisation and says many of the people involved in the earlier work remain involved today. Wellbeing International Foundation

But when this investigation began following that history backwards, we repeatedly encountered the same things.

Stephen Ray.

Andrew Chancellor.

Earlier biotechnology companies.

Microvesicle patents.

A German laboratory relationship.

10 Harley Street.

And scientific protocols involving cells, secreted biological material and extracellular vesicles.

Eventually, the question became unavoidable.

Was Wellbeing really the beginning of this operation?

Or was it the latest corporate chapter in a scientific and commercial project that had already existed for years?

Wellbeing Itself Says the Story Started Earlier

Interestingly, Wellbeing does not claim that everything began when the present organisation appeared.

Quite the opposite.

Its current historical account explicitly reaches backwards.

Wellbeing says its present cell-free, autologous research approach is the result of work refined across decades, describing earlier Swiss research, subsequent partnerships with researchers in Britain and Europe, and the continuing involvement of Stephen Ray. Wellbeing International Foundation

Another retrospective article on Wellbeing's own site acknowledges that its research partners and cell sources have changed over time while saying that the underlying biological principles remained. Wellbeing International Foundation

That is significant.

Because Wellbeing itself is describing continuity.

The question is what that continuity consisted of.

People?

Science?

Protocols?

Companies?

Intellectual property?

Laboratory relationships?

Or some combination of all of them?

The Trail Begins Before Wellbeing

Long before the modern Wellbeing website, Stephen Ray was working with microvesicles.

Patent records establish this independently.

An international patent application filed in January 2009 identifies:

Stephen Ray — Inventor

and:

Lydac Neuroscience Limited — Applicant/Assignee

for an invention titled:

Microvesicles. Google Patents

The European member of that patent family, EP2240189B1, describes methods for producing microvesicles, including immunologically matched autologous microvesicles for potential therapeutic and other applications. Google Patents

This is important because extracellular vesicles now sit prominently within the scientific explanation surrounding Wellbeing's Cell-Free Therapy.

It does not establish that today's CFT is the patented Lydac technology.

We have found no evidence allowing us to make that leap.

But it establishes something more fundamental:

the scientific theme existed before modern Wellbeing.

And So Did Stephen Ray

Lydac Neuroscience was incorporated in 2007 as a biotechnology research company.

Stephen Ray became a director at incorporation.

He remained a director until 2012.

So years before prospective Wellbeing patients were sitting opposite Ray at Harley Street hearing explanations about extracellular vesicles, Ray was already commercially involved in a biotechnology company whose patent portfolio included microvesicle technology.

That is not similarity discovered with hindsight.

It is documented scientific history.

Then Andrew Chancellor Appears

Andrew Chancellor entered this scientific-commercial story later.

His background was primarily business.

Banking.

International recruitment.

Executive search.

Then biotechnology.

Companies House records place Chancellor in biotechnology-related businesses from 2010 onward.

And eventually he appears in Lydac Neuroscience itself.

On 26 November 2014, Chancellor became a director of Lydac.

Ray had already left more than two years earlier.

We should therefore be precise:

Ray and Chancellor were not directors of Lydac at the same time.

But that isn't the end of the relationship.

Because Chancellor subsequently described a much earlier working relationship with Ray himself.

And he did so in his own words.

The Conversation That Changes the Timeline

In January 2021, an investigator posing as a prospective patient participated in a video meeting concerning the German laboratory used in the treatment process.

Andrew Chancellor attended.

The discussion turned to the history of the relationship.

Chancellor explained:

“Steve and I have worked with [the German laboratory connection] since 2011 and when we were both in different companies.”

He then went further.

Chancellor said they had worked together since approximately:

“2010 or 2011.”

And he described Ray's role:

“Steve designs all the protocols that we use.”

The German laboratory representative described the relationship as even older, saying he thought the parties had originally been working together since approximately 2008.

The precise starting year therefore differs between the recollections.

But the central point does not.

The relationship substantially predates modern Wellbeing.

Then Chancellor Said Something Even More Important

During that same conversation, Chancellor described the earlier corporate arrangement.

His wording is significant.

He referred to himself and Ray as having been associated with an earlier company and described that business as having:

“now turned into Wellbeing.”

That statement deserves considerably more investigation.

Because “turned into” can mean many things in ordinary conversation.

It could describe commercial evolution.

It could describe personnel moving from one business into another.

It could describe a project being continued through another legal entity.

It does not, by itself, prove a legal corporate succession.

We therefore should not interpret Chancellor's words more broadly than the evidence allows.

But they are his words.

And they contradict any simplistic picture of Wellbeing appearing independently from nowhere.

The CEO himself was describing a predecessor relationship.

This Was Already a Network

Now place another part of Chancellor's statement beside it.

He said:

“Stephen and [the German laboratory connection] have worked closely together, because Steve designs all the protocols that we use.”

That gives us three components operating around the same historical period.

Ray — science and protocols.

Chancellor — commercial involvement.

Germany — laboratory processing.

Those same three components remain recognisable in the modern Wellbeing structure.

Today Wellbeing publicly describes a patient pathway in which blood is collected at an approved location, transported under controlled conditions to a German laboratory, processed and tested there, and subsequently returned for infusion at an approved clinical location. Wellbeing International Foundation

The names of companies and the details of the process may have evolved.

But the architecture is remarkably familiar.

The German Laboratory Is Therefore Not a New Development

Chapter Two asked whether Wellbeing owned its clinics.

Now we need to ask the same thing about its laboratory history.

During the recorded 2021 meeting, the German representative described operating a laboratory according to GMP standards and said:

“We carry out the protocols of Wellbeing International.”

He described his role as involving quality control and process control.

Chancellor, meanwhile, described Ray as designing the protocols.

That creates a remarkably clear historical division of functions.

Ray develops or designs protocols.

The German laboratory performs processing.

Chancellor sits within the commercial organisation coordinating the operation.

Today Wellbeing describes its German facility as a laboratory partner and elsewhere describes it as GMP-certified. Wellbeing International Foundation

The relationship may have changed substantially since the recorded conversation.

But the underlying structure appears to have existed for years.

What Was Actually Happening in Germany?

The historical laboratory conversation gives us considerably more detail.

The German representative explained that cells were isolated and then subjected to a protocol intended to cause them to release biological substances into the surrounding medium.

Among the substances he mentioned were:

cytokines;

microvesicles;

and growth factors.

This is particularly important because it connects the historical laboratory process directly back to the terminology we already found in Ray's earlier patent work.

Microvesicles.

Again, this does not establish that the German laboratory was practising Lydac's patented invention.

Nor does it establish that Wellbeing's present CFT is legally derived from that patent.

Those are separate questions.

But scientifically and historically, the recurring terminology is impossible to ignore.

Lydac Provides Another Piece of the Puzzle

Return to Lydac.

By 2014, Chancellor was a director.

In June 2015, Lydac moved its registered office to:

10 Harley StreetLondonW1G 9PF.

Then in December 2015 the European microvesicle patent associated with Ray and Lydac reached grant. Google Patents

Three years later, Lydac failed.

Administrators were appointed on 17 December 2018.

The official Gazette records both its registered office and principal trading address as:

10 Harley Street. The Gazette

It subsequently moved into creditors' voluntary liquidation in November 2019. The Gazette

At first glance, that appears to be the end of Lydac.

But then our physical investigation took us somewhere familiar.

Back to 10 Harley Street

In November 2020, an investigator approached Wellbeing as a prospective patient.

The consultation took place at:

10 Harley Street.

The same address.

Inside, Stephen Ray did much of the talking.

The proposed process was explained.

Blood would be collected.

It would be sent to Germany.

Cells would be processed.

Extracellular vesicles would be harvested.

The resulting preparation would return.

It would then be administered intravenously.

This is where the history becomes difficult to dismiss as merely a collection of unrelated facts.

Lydac's principal trading address in 2018:

10 Harley Street.

The location of the subsequent Wellbeing consultation:

10 Harley Street.

Ray's earlier science:

microvesicles.

The later consultation:

extracellular vesicles.

Earlier laboratory relationship:

Germany.

Later Wellbeing processing:

Germany.

Andrew Chancellor:

director of the earlier biotechnology company and subsequently CEO of Wellbeing.

Stephen Ray:

inventor associated with the earlier microvesicle patent and subsequently Wellbeing's senior scientific figure.

Those points do not prove that Lydac became Wellbeing.

But they establish a degree of continuity that requires explanation.

And Lydac Wasn't Necessarily the Immediate Predecessor

This is an important distinction.

It would be easy to write:

Lydac became Wellbeing.

We cannot establish that.

In fact, Chancellor's own recorded explanation points towards a more complicated chain.

He described himself and Ray as being associated with another earlier company and said that business had subsequently “turned into Wellbeing.”

Meanwhile, Lydac existed alongside parts of this history.

That suggests we may not be looking at a simple:

Company A → Company B.

Instead we may be looking at an interconnected scientific and commercial ecosystem.

Different companies.

Overlapping personnel.

Laboratory relationships.

Patents.

Protocols.

Clinical delivery arrangements.

And eventually Wellbeing International Foundation.

That distinction is crucial.

The Corporate Vehicle May Have Changed More Than the Project

This possibility is reinforced by Wellbeing's own modern historical account.

Wellbeing says its programme evolved through different cell sources and research relationships while retaining an underlying biological approach. Wellbeing International Foundation

That is essentially a description of scientific continuity through organisational change.

And there is nothing inherently improper about that.

Scientific projects routinely outlive individual companies.

Researchers move.

Businesses restructure.

Laboratory partners change.

Intellectual property is licensed or assigned.

New companies raise capital to commercialise earlier research.

But when that happens, there should normally be a documentary trail.

And that is what we are looking for.

The Missing Bridge

We can document Ray's earlier microvesicle work.

We can document Lydac.

We can document Chancellor's later directorship of Lydac.

We can document Lydac at 10 Harley Street.

We can document its administration and liquidation.

We have Chancellor's own historical description of working with Ray and the German laboratory relationship around 2010/2011.

We have the German laboratory representative describing a long-standing relationship and carrying out Wellbeing protocols.

We have physical evidence of Wellbeing consultations subsequently taking place at 10 Harley Street.

And today we have Wellbeing publicly describing a German-laboratory/clinical-network model. Wellbeing International Foundation

What we do not yet have is the documentary bridge explaining how all of those pieces legally connect.

That may be the most important missing document in this entire investigation.

Did Wellbeing Acquire Anything?

If Wellbeing is a continuation of earlier scientific work, there are obvious questions.

Did it acquire intellectual property?

Did it acquire licences?

Did it acquire laboratory protocols?

Did it acquire patient data?

Did it acquire cell banks or stored biological material?

Did it acquire research records?

Did it acquire contractual rights?

Did it acquire know-how?

Or did Stephen Ray simply bring his personal scientific expertise into an entirely new organisation?

Those are very different scenarios.

And they matter enormously.

Especially now that Wellbeing is seeking private investment.

The Patent Doesn't Follow the Scientist Automatically

This distinction is fundamental.

Stephen Ray was the inventor named on the microvesicle patent.

But Lydac was the assignee identified in the patent records. Google Patents

Inventorship and ownership are not the same thing.

A scientist can continue to possess knowledge after leaving a company.

He does not necessarily continue to own intellectual property that has previously been assigned to that company.

Likewise, Andrew Chancellor later becoming a Lydac director does not mean Chancellor personally owned Lydac's patents.

The company owned its assets.

So if modern Wellbeing technology substantially derives from earlier protected technology, the legal chain matters.

Where is it?

Perhaps Today's CFT Is Entirely Different

There is another possibility that must be considered.

Modern CFT may be sufficiently different from the old Lydac technology that the historical patents simply aren't relevant to its legal ownership.

Wellbeing itself says its programme has evolved significantly over time and that the specific cell sources it works with today differ from those used in earlier periods. Wellbeing International Foundation

That could provide an entirely legitimate explanation.

But it produces another question.

If today's technology is materially different, when was the new technology developed?

By whom?

Within which legal entity?

Who paid for its development?

Who owns it?

Was it patented?

Was it deliberately kept as trade-secret know-how?

And what documentation establishes Wellbeing's exclusive right to commercialise it?

Either route leads back to ownership.

This Is Why the History Matters

Imagine stripping away the company names.

What remains?

A scientist associated with microvesicle research.

A businessman involved with biotechnology commercialisation.

A German laboratory relationship.

Protocols designed by the scientist.

Biological samples processed in Germany.

Clinical delivery performed elsewhere.

Harley Street consultations.

Extracellular-vesicle biology.

Private patients.

Private capital.

That structure appears repeatedly across the historical record.

Companies change.

The core ingredients appear considerably more persistent.

And that is why simply asking when Wellbeing International Foundation was incorporated does not answer the real question.

We need to know when the operation behind Wellbeing began.

What We Can Say — and What We Cannot

The evidence now supports several conclusions.

Wellbeing's scientific history predates its modern public identity.

Stephen Ray's documented work involving microvesicles goes back at least to the patent applications originating in 2008/2009. Google Patents

Ray was associated with Lydac Neuroscience.

Chancellor subsequently became a Lydac director.

Lydac later operated from 10 Harley Street. The Gazette

Chancellor described himself and Ray as having worked within the German laboratory relationship since approximately 2010/2011.

A German laboratory representative independently described the relationship as longstanding.

Wellbeing consultations subsequently occurred at 10 Harley Street.

And Wellbeing today continues to use a German laboratory within its treatment architecture. Wellbeing International Foundation

What we cannot currently establish is equally important.

We cannot say Lydac legally became Wellbeing.

We cannot say Wellbeing acquired Lydac's patents.

We cannot say Lydac's intellectual property was improperly transferred.

We cannot say today's CFT infringes or uses the old patents.

And we cannot yet establish the complete legal succession between every company involved.

That is exactly why this investigation continues.

The Question Has Changed Again

At the beginning of this chapter we asked:

What existed before Wellbeing?

We now have part of the answer.

A great deal existed.

The science existed.

The people existed.

The laboratory relationships existed.

The biotechnology businesses existed.

The protocols were developing.

Microvesicles were already part of Ray's work.

And the commercial relationships around that science were forming years before the organisation investors and patients see today.

So perhaps the most important question is no longer:

When was Wellbeing founded?

It is:

When did the operation that eventually became Wellbeing actually begin?

And then comes the question that may finally connect everything:

What moved from the earlier organisations into Wellbeing — and where are the documents proving it?

That is where we go next.

Next: Chapter Five — The Missing Bridge: What Actually Moved Into Wellbeing?

Companies can disappear while science, contracts, data, protocols and intellectual property survive. We now follow the assets rather than the people: patents, licences, laboratory protocols, patient data, stored biological material and scientific know-how. If Wellbeing is the continuation of decades of research, what exactly crossed the bridge from the organisations that came before it — and who owns it today?